Evidence map›Paper›PMID 27859137›Full record

ArticleInternational journal of cancer2017

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.

Clara Bodelon, Hannah Oh, Nilanjan Chatterjee, Montserrat Garcia-Closas, Maya Palakal, Mark E Sherman, Ruth M Pfeiffer, Berta Geller, Pamela Vacek, Donald L Weaver and 16 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020
    Review
  3. Article
  4. PDE4 subtypes in cancer.Oncogene · 2020
    Review
  5. Article
  6. Article
  7. Proof of region-specific multipotent progenitors in human breast epithelia.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 2 countries.

Clara BodelonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Hannah OhDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Nilanjan ChatterjeeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Maya PalakalDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Mark E ShermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Berta GellerThe University of Vermont, Burlington, VT.
Pamela VacekThe University of Vermont, Burlington, VT.
Donald L WeaverThe University of Vermont, Burlington, VT.
Rachael ChicoineThe University of Vermont, Burlington, VT.
Daphne PapathomasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Jackie XiangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Deesha A PatelDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Zeina G KhodrDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Laura LinvilleDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Susan E ClareDepartment of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Daniel W VisscherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Carolyn MiesDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Stephen M HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Anna Maria V StornioloSusan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN.
Chunyan HeDepartment of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Gretchen L Gierach *Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Jonine D Figueroa *Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
National Cancer Institute · USDivision of Cancer Epidemiology and GeneticsUniversity of Vermont · USCenter for Cancer Research · USEdinburgh Cancer Research · GBIndiana University IndianapolisIndiana University – Purdue University Indianapolis · USMayo Clinic in Arizona · USNorthwestern University · USUniversity of Pennsylvania · US

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
VERMONT BREAST CANCER SURVEILLANCE SYSTEMU01CA070013 · NCI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI GELLER, BERTA M · 1995 to 2011
$6.7M
Intramural NIH HHS Z99 CA999999NCI NIH HHS U01 CA070013
6 · The paper itself

Abstract

Terminal duct lobular units (TDLUs) are the predominant source of future breast cancers, and lack of TDLU involution (higher TDLU counts, higher acini count per TDLU and the product of the two) is a breast cancer risk factor. Numerous breast cancer susceptibility single nucleotide polymorphisms (SNPs) have been identified, but whether they are associated with TDLU involution is unknown. In a pooled analysis of 872 women from two studies, we investigated 62 established breast cancer SNPs and relationships with TDLU involution. Poisson regression models with robust variance were used to calculate adjusted per-allele relative risks (with the non-breast cancer risk allele as the referent) and 95% confidence intervals between TDLU measures and each SNP. All statistical tests were two-sided; P < 0.05 was considered statistically significant. Overall, 36 SNPs (58.1%) were related to higher TDLU counts although this was not statistically significant (p = 0.25). Six of the 62 SNPs (9.7%) were nominally associated with at least one TDLU measure: rs616488 (PEX14), rs11242675 (FOXQ1) and rs6001930 (MKL1) were associated with higher TDLU count (p = 0.047, 0.045 and 0.031, respectively); rs1353747 (PDE4D) and rs6472903 (8q21.11) were associated with higher acini count per TDLU (p = 0.007 and 0.027, respectively); and rs1353747 (PDE4D) and rs204247 (RANBP9) were associated with the product of TDLU and acini counts (p = 0.024 and 0.017, respectively). Our findings suggest breast cancer SNPs may not strongly influence TDLU involution. Agnostic genome-wide association studies of TDLU involution may provide new insights on its biologic underpinnings and breast cancer susceptibility.

Indexed as

Genes, NeoplasmPolymorphism, Single NucleotideAdolescentAdultAgedAged, 80 and overAge FactorsAllelesBiopsyBreast NeoplasmsCase-Control StudiesCross-Sectional StudiesFemaleGenetic Predisposition to DiseaseHumansMammary Glands, Humanbreast cancergenetic susceptibilityinvolutionterminal duct lobular unit

Identifiers

PMID27859137
PMCPMC5167645
OpenAlexW2554190181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.